Related references
Note: Only part of the references are listed.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
Messoud Ashina et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2021)
Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies
Tina M. Oakes et al.
HEADACHE (2020)
Vascular safety of erenumab for migraine prevention
David Kudrow et al.
NEUROLOGY (2020)
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
Kathleen Mullin et al.
NEUROLOGY (2020)
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
Bixi Gao et al.
FRONTIERS IN PHARMACOLOGY (2020)
Migraine and risk of stroke
Lise R. Oie et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
Inge A. Mulder et al.
ANNALS OF NEUROLOGY (2020)
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache
Jill C. Rau et al.
CEPHALALGIA (2020)
Medication overuse headache: Divergent effects of new acute antimigraine drugs
Philip R. Holland et al.
CEPHALALGIA (2020)
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
Edita Navratilova et al.
CEPHALALGIA (2020)
Differential medication overuse risk of novel anti-migraine therapeutics
Chonlawan Saengjaroentham et al.
BRAIN (2020)
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
Gary Berman et al.
HEADACHE (2020)
Targeting CGRP in migraine: a matter of choice and dose
Linda Al-Hassany et al.
LANCET NEUROLOGY (2020)
Antagonism of CGRP Signaling by Rimegepant at Two Receptors
Kylie S. Pan et al.
FRONTIERS IN PHARMACOLOGY (2020)
CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
Valentina Favoni et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials
Stephen D. Silberstein et al.
HEADACHE (2019)
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2019)
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
Richard B. Lipton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
Peer Tfelt-Hansen et al.
HEADACHE (2019)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Migraine is first cause of disability in under 50s: will health politicians now take notice?
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan
K. Ibrahimi et al.
CEPHALALGIA (2017)
Wiping Out CGRP: Potential Cardiovascular Risks
Antoinette MaassenVanDenBrink et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
Ronald Marcus et al.
CEPHALALGIA (2014)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
Tony W. Ho et al.
NEUROLOGY (2014)
Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
G. Tong et al.
JOURNAL OF HEADACHE AND PAIN (2013)
Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain
Rodrigo Noseda et al.
PAIN (2013)
Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine
Guanglin Luo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
Hans-Christoph Diener et al.
CEPHALALGIA (2011)
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
David J. Hewitt et al.
CEPHALALGIA (2011)
Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
Jakob Moller Hansen et al.
CEPHALALGIA (2010)
Randomized, controlled trial of telcagepant for the acute treatment of migraine
K. M. Connor et al.
NEUROLOGY (2009)
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
T. W. Ho et al.
NEUROLOGY (2008)
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack
G Juhasz et al.
CEPHALALGIA (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
CGRP may play a causative role in migraine
LH Lassen et al.
CEPHALALGIA (2002)
Share Paper
